Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00451204 · ClinicalTrials.gov registry record · Phase 2

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

A Phase 2 study of Relapsing Remitting Multiple Sclerosis, sponsored by University of California, Los Angeles.

Completed
Registry status
Phase 2
Development phase
158
Enrollment target
16
Study locations

NCT00451204 is a Phase 2 study of Relapsing Remitting Multiple Sclerosis that has completed, run by University of California, Los Angeles. The registered enrollment target is 158 participants, below the 196-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (19% lower). The trial reports 16 study locations across 16 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00451204, a Phase 2 study of Relapsing Remitting Multiple Sclerosis, has completed, sponsored by University of California, Los Angeles.

COMPLETED
Registry status
Phase 2
Development phase
158 participants
Enrollment target
16
Study locations

Study Summary

This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects. The primary outcome measure is a reduction in relapses.

Conditions Studied

Relapsing Remitting Multiple Sclerosis

Interventions

  • DRUG Placebo
  • DRUG Estriol
  • DRUG Copaxone

Study Locations (16)

Arizona

  • Mayo Clinic - Scottsdale

California

  • University of California, Los Angeles - Los Angeles

Colorado

  • University of Colorado - Aurora

Illinois

  • University of Chicago - Chicago

Kansas

  • University of Kansas - Kansas City

Maryland

  • Johns Hopkins University - Baltimore

Minnesota

  • University of Minnesota - Minneapolis

Missouri

  • Washington University - St Louis

Trial Details

FieldValue
Enrollment Target 158 participants
Start Date 2007-03
Est. Completion 2014-07
Phase Phase 2

Sponsor

University of California, Los Angeles

897 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00451204

The ClinicalTrials.gov registry entry for NCT00451204 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (19% lower). The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT00451204 reports 16 study locations spanning 16 distinct geographic areas - top geographies include Arizona, California, Colorado.

Frequently Asked Questions

What is clinical trial NCT00451204 about?

NCT00451204 is a clinical study titled "A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)". This is a double-blinded, placebo controlled study of estriol pills versus placebo pills in relapsing remitting multiple sclerosis. The study treatment will be an added on to Copaxone injections in all subjects. The primary outcome measure is a reduction in relapses.

What is the current status of trial NCT00451204?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 158 participants. The study started on 2007-03. Estimated completion is 2014-07.

What conditions does trial NCT00451204 study?

This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.

What interventions are being tested in trial NCT00451204?

The interventions under investigation include: Placebo (DRUG), Estriol (DRUG), Copaxone (DRUG).

Who is sponsoring clinical trial NCT00451204?

This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00451204 being conducted?

This trial has 16 study locations across Arizona, California, Colorado, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Relapsing Remitting Multiple Sclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Relapsing Remitting Multiple Sclerosis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.